Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464291 | 1.00 | TAAR1 (0.55) | TAAR1GAAHTTATMNPSR1 | |
| SCHEMBL779716 | 0.85 | TAAR1 (0.44) | TAAR1GAAHTTNPSR1TDP1 | |
| SCHEMBL1008876 | 0.85 | TAAR1 (0.39) | TAAR1GAAATMTDP1KMT2A | |
| SCHEMBL14127180 | 0.82 | TAAR1 (0.57) | TAAR1GAAHTTATMNPSR1 | |
| SCHEMBL6388715 | 0.82 | TAAR1 (0.57) | TAAR1GAAHTTATMNPSR1 | |
| SCHEMBL2032212 | 0.81 | TAAR1 (0.61) | TAAR1GAAHTTATMNPSR1 | |
| SCHEMBL31454642 | 0.80 | MEN1 (0.34) | TAAR1GAAATMTDP1KMT2A | |
| SCHEMBL1627070 | 0.80 | TAAR1 (0.38) | TAAR1GAAHTTNPSR1TDP1 | |
| SCHEMBL31454481 | 0.80 | TAAR1 (0.38) | TAAR1GAAHTTNPSR1TDP1 | |
| SCHEMBL1294116 | 0.78 | GRIA1 (0.43) | TAAR1HTTKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368092-A1 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-11-07 | — | — | US | disclosed |
| EP-4396181-A1 | 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS | Breye Therapeutics ApS (DK) | 2024-07-10 | — | — | EP | disclosed |
| CN-117881675-A | 2, 4-dihydro-3H-1, 2, 4-triazol-3-one P2X7 antagonists | 布雷耶疗法有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-116804004-A | Compounds as DHODH inhibitors | 南京征祥医药有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20230271943-A1 | COMPOUNDS AS DHODH INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271943-A1 | COMPOUNDS AS DHODH INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| CN-116457343-A | Compounds as DHODH inhibitors | 南京征祥医药有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4185577-A1 | COMPOUNDS AS DHODH INHIBITORS | Nanjing Zenshine Pharmaceuticals Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| CN-111253404-B | Nitrogen-containing heterocyclic compound and composition, preparation method and application thereof | 上海医药集团股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | disclosed |
| EP-0251775-B1 | ALPHA-ARYL-ALPHA-PHENYLETHYL-1H-1,2,4-TRIAZOLE-1-PROPANENITRILES | ROHM AND HAAS COMPANY (US) | 1993-01-20 | — | — | EP | disclosed |
| EP-0349358-B1 | PROCESS FOR PRESULFIDING AND CONTROLLING THE ACTIVITY OF A HYDROCARBON TREATMENT CATALYST | EURECAT EUROPEENNE DE RETRAITEMENT DE CATALYSEURS (FR) | 1992-03-04 | — | — | EP | disclosed |
| US-5087635-A | Funcicides | ROHM AND HAAS COMPANY (US) | 1992-02-11 | — | — | US | disclosed |
| US-5059731-A | Selectively hydrogenating acetylenic and diolefinic hydrocarbons | EUROPEANE DE RETRAITEMENT DE CATALYSEURS EURECAT (FR) | 1991-10-22 | — | — | US | disclosed |
| US-4983559-A | CATALYTIC REGENERATION | EUROPEENE DE RETRAITEMENT DE CATALYSEURS EURECAT (FR) | 1991-01-08 | — | — | US | disclosed |
| EP-0349358-A1 | Process for presulfiding and controlling the activity of a hydrocarbon treatment catalyst | EURECAT EUROPEENNE DE RETRAITEMENT DE CATALYSEURS (FR) | 1990-01-03 | — | — | EP | disclosed |
| EP-0251775-A2 | Alpha-aryl-alpha-phenylethyl-1H-1,2,4-triazole-1-propanenitriles | ROHM AND HAAS COMPANY (US) | 1988-01-07 | — | — | EP | disclosed |
| US-4399076-A | 1,1-Disubstituted 2-vinyl- and 2-ethylcyclopropanes | NATIONAL DISTILLERS AND CHEMICAL CORPORATION (US) | 1983-08-16 | — | — | US | disclosed |
| US-4369322-A | WITH CYANOGEN CHLORIDE | DEGUSSA AG (DE) | 1983-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11623919-B2 | Heterocyclic P2X7 antagonists | P2RY1, P2RX1, P2RX3 | TAAR1 240/4885GAA 4101/4885HTT 835/4885 |
| US-20230271943-A1 | COMPOUNDS AS DHODH INHIBITORS | DHODH, DLD, DHRS9 | TAAR1 4107/4885GAA 273/4885HTT 539/4885 |
| US-20240368092-A1 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | P2RX3, P2RX7, P2RX2 | TAAR1 666/4885GAA 3011/4885HTT 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.